Effect of fluoxetine on depression-induced changes in the expression of vasoactive intestinal polypeptide and corticotrophin releasing factor in rat duodenum

Table 1 Open-field activities and sucrose intake test of rats (n = 10, mean ± SD)

Group	Crossing/5 min	Rearing/5 min	Defecation/5 min	Sucrose intake mL/24 h
Control	133.00 ± 11.309	28.53 ± 10.22	3.90 ± 0.57	36.18 ± 10.24
Saline + depressed	51.80 ± 7.441b	11.10 ± 5.18b	6.80 ± 0.57b	8.95 ± 7.39b
FH + depressed	76.60 ± 3.534d	15.58 ± 7.367d	5.10 ± 0.43d	18.10 ± 6.43d

FH: Fluoxetine hydrochloride.

^bP < 0.01 vs control group;

^dP < 0.01 vs saline-treated depressed group.

Table 2 Changes of levels of VIP/CRF in plasma (n = 10, mean ± SD)

Group	VIP in Plasma (ng/L)	CRF in Plasma (ng/L)
Control	67.37 ± 18.90	11.82 ± 2.54
Saline + depressed	44.51 ± 16.37b	25.17 ± 4.63b
FH + depressed	60.86 ± 19.27d	17.05 ± 3.69d

^bP < 0.01 vs control group;

^dP < 0.01 vs saline-treated depressed group.

Table 3 The average fluorescence intensity analysis of VIP and CRF alterations in duodenum of depression model rats (n = 10, mean ± SD)

Group	Fluorescence intensity of VIP	Fluorescence intensity of CRF
Control	36.28 ± 17.16	10.87 ± 9.28
Saline + depressed	19.07 ± 13.84b	50.83 ± 24.66b
FH + depressed	28.29 ± 15.02d	29.18 ± 17.34d

FH: Fluoxetine hydrochloride; VIP: Vasoactive intestinal polypeptide; CRF: Corticotrophin releasing factor.

^bP < 0.01 vs control group;

^dP < 0.01 vs saline-treated depressed group.